NCT00679211View on ClinicalTrials.gov

A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

April 30, 2011

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Trastuzumab emtansine [Kadcyla]

Intravenous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT00679211 - A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter